These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 31766908)

  • 21. Lasmiditan for acute treatment of migraine.
    Parikh S
    Drugs Today (Barc); 2021 Feb; 57(2):89-100. PubMed ID: 33656015
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lasmiditan: an additional therapeutic option for the acute treatment of migraine.
    Martinelli D; Bitetto V; Tassorelli C
    Expert Rev Neurother; 2021 May; 21(5):491-502. PubMed ID: 33866907
    [No Abstract]   [Full Text] [Related]  

  • 23. Serotonin receptor targeted therapy for migraine treatment: an overview of drugs in phase I and II clinical development.
    Barbanti P; Aurilia C; Egeo G; Fofi L; Palmirotta R
    Expert Opin Investig Drugs; 2017 Mar; 26(3):269-277. PubMed ID: 28103158
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lasmiditan for Acute Treatment of Migraine in Adults: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Yang Y; Sun Y; Gao B; Wang Z; Chen Z; Wang Z
    CNS Drugs; 2020 Oct; 34(10):1015-1024. PubMed ID: 32857291
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Profile of Lasmiditan in the Acute Treatment of Migraine in Adults: Design, Development, and Place in Therapy.
    Anderson CC; VanderPluym JH
    Drug Des Devel Ther; 2023; 17():1979-1993. PubMed ID: 37426628
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study).
    Brandes JL; Klise S; Krege JH; Case M; Khanna R; Vasudeva R; Raskin J; Pearlman EM; Kudrow D
    Cephalalgia; 2019 Oct; 39(11):1343-1357. PubMed ID: 31433669
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety findings from Phase 3 lasmiditan studies for acute treatment of migraine: Results from SAMURAI and SPARTAN.
    Krege JH; Rizzoli PB; Liffick E; Doty EG; Dowsett SA; Wang J; Buchanan AS
    Cephalalgia; 2019 Jul; 39(8):957-966. PubMed ID: 31166697
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety Findings in Lasmiditan as a Novel Acute Treatment of Migraine in Chinese Patients: A Post Hoc Analysis of the Randomized Controlled Phase 3 CENTURION Trial.
    Zhou J; Luo G; Xu Y; Yang X; Pan X; Dong Z; Zhong S; Liu H; Ji F; Yu S
    Adv Ther; 2022 Nov; 39(11):5229-5243. PubMed ID: 36114949
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lasmiditan for the acute treatment of migraine.
    DeJulio PA; Perese JK; Schuster NM; Oswald JC
    Pain Manag; 2021 Sep; 11(5):437-449. PubMed ID: 33840206
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase 2 randomized placebo-controlled study of lasmiditan for the acute treatment of migraine in Japanese patients.
    Sakai F; Takeshima T; Homma G; Tanji Y; Katagiri H; Komori M
    Headache; 2021 May; 61(5):755-765. PubMed ID: 33990951
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lasmiditan mechanism of action - review of a selective 5-HT
    Clemow DB; Johnson KW; Hochstetler HM; Ossipov MH; Hake AM; Blumenfeld AM
    J Headache Pain; 2020 Jun; 21(1):71. PubMed ID: 32522164
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rational Use of Lasmiditan for Acute Migraine Treatment in Adults: A Narrative Review.
    Ferrari A; Rustichelli C
    Clin Ther; 2021 Apr; 43(4):654-670. PubMed ID: 33608115
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and tolerability of 100 mg of lasmiditan for migraine: A multi-center, prospective observational real-world study in Japan.
    Ishii R; Ishizuchi K; Watanabe N; Fukazawa R; Trivedi M; Nakahara J; Takizawa T
    Cephalalgia; 2024 Jun; 44(6):3331024241258695. PubMed ID: 38859749
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study.
    Färkkilä M; Diener HC; Géraud G; Láinez M; Schoenen J; Harner N; Pilgrim A; Reuter U;
    Lancet Neurol; 2012 May; 11(5):405-13. PubMed ID: 22459549
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lasmiditan (Reyvow) for the Treatment of Acute Migraine.
    Marshall C; Torro J
    Am Fam Physician; 2020 Dec; 102(12):756-757. PubMed ID: 33320510
    [No Abstract]   [Full Text] [Related]  

  • 36. Is selective 5-HT
    Rubio-Beltrán E; Labastida-Ramírez A; Villalón CM; MaassenVanDenBrink A
    Pharmacol Ther; 2018 Jun; 186():88-97. PubMed ID: 29352859
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The selective 5-HT
    Vila-Pueyo M; Page K; Murdock PR; Loraine HJ; Woodrooffe AJ; Johnson KW; Goadsby PJ; Holland PR
    Br J Pharmacol; 2022 Feb; 179(3):358-370. PubMed ID: 34600443
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials.
    Loo LS; Ailani J; Schim J; Baygani S; Hundemer HP; Port M; Krege JH
    J Headache Pain; 2019 Jul; 20(1):84. PubMed ID: 31340760
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Budget impact of lasmiditan for the acute treatment of migraine in the United States.
    Milev S; Pohl G; Sun A; Mason O; Njuguna N; Loo LS
    J Manag Care Spec Pharm; 2021 Dec; 27(12):1714-1723. PubMed ID: 34818093
    [No Abstract]   [Full Text] [Related]  

  • 40. Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: findings from the phase 3 trials (SAMURAI and SPARTAN).
    Loo LS; Plato BM; Turner IM; Case MG; Raskin J; Dowsett SA; Krege JH
    BMC Neurol; 2019 Aug; 19(1):191. PubMed ID: 31409292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.